GleamWall
中文EN

JAGX Jaguar Health, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1585608 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY129.7%
TTM net income YoY18.7%
TTM EPS YoY199.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin81.5%
Operating margin-91.2%
Net margin-121.0%
FCF margin—
EBITDA margin-84.2%

Returns

ROE-252.4%
ROA-79.9%
ROIC (approx.)-230.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets42.7%
Debt / equity0.00x
Current ratio1.28x
Interest coverage-21.50x

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-63.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.34M$1.23M$20.27M$3.23M$3.08M$2.98M$2.21M$3.51M
Cost of revenue$627,000$1.03M$1.16M$2.20M$532,000$527,000$515,000$557,000
Gross profit$1.72M$194,000$19.11M$1.03M$2.55M$2.45M$1.70M$2.95M
R&D expense$3.61M$3.34M$3.93M$14.31M$3.66M$3.27M$3.73M$4.53M
SG&A expense$4.08M$4.45M$4.11M$4.89M$4.13M$4.73M$4.90M$3.86M
Operating income-$6.02M-$7.60M$10.18M-$21.24M-$7.24M-$8.01M-$9.42M-$8.16M
Interest expense$156,000$161,000$699,000$132,000$6,000-$15,000-$56,000-$110,000
Pretax income-$5.83M-$12.80M$8.72M-$23.19M-$9.65M-$10.56M-$10.60M-$10.23M
Income tax$0$0$0$0$0$0$0$0
Net income-$5.71M-$12.68M$8.85M-$23.20M-$9.50M-$10.41M-$10.46M-$9.92M
EBITDA-$5.55M-$7.12M$10.65M-$20.77M-$6.76M-$7.53M-$8.94M-$7.68M
EPS (basic)-9.23-15.70-13.60—-2,032.95-358.94-584.45—
EPS (diluted)-9.23-15.70-13.60—-2,032.95-358.94-584.45—
Weighted avg. shares (diluted)684,374809,122515,788—4,67428,99417,904—
Balance sheet
Cash & equivalents$5.53M$3.79M$7.28M$968,000$3.53M$2.21M$5.69M$8.00M
Receivables$554,000$8,000$68,000$1.52M$1.44M$1.17M$1.22M$1.53M
Inventory$6.75M$7.32M$7.82M$8.60M$10.63M$10.72M$10.55M$10.35M
Current assets$16.39M$17.53M$20.21M$20.34M$29.40M$27.90M$30.44M$32.20M
PP&E, net$412,000$417,000$423,000$463,000$483,000$441,000$452,000$464,000
Intangibles$14.62M$15.09M$15.55M$16.02M$17.29M$17.55M$18.01M$18.48M
Total assets$32.51M$34.19M$37.43M$38.32M$49.47M$48.27M$51.46M$53.42M
Current liabilities$12.83M$25.38M$40.69M$40.65M$36.12M$29.22M$28.21M$19.70M
Total liabilities$13.89M$29.27M$53.19M$57.01M$45.11M$41.39M$48.15M$44.45M
Shareholders' equity$20.32M$6.62M-$14.18M-$17.29M$5.63M$7.99M$1.78M$7.29M
Cash flow statement
Operating cash flow-$4.93M-$5.34M$8.83M-$5.49M-$4.69M-$6.19M-$7.31M-$7.83M
Capital expenditure———————$0
Free cash flow———————-$7.83M
Investing cash flow———$13,000———-$215,000
Financing cash flow$3.85M$1.86M-$6.62M$9.79M$6.26M$2.65M$4.97M$2.83M
Depreciation & amortization$473,000$473,000$473,000$477,000$479,000$478,000$479,000$478,000
Stock-based compensation$168,000$171,000$155,000$116,000$135,000$279,000$301,000$372,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.